As a Free StocksGuide user, you can view scores for all 7,031 stocks worldwide.
15 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:
15 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:
| Jun '25 | 
         
    +/-
   
  
    %
   
 | 
      ||
| Revenue | 2,305 2,305 | 
         
      
        
        3%
      
      
        
        3%
      
 
        
       | 
      |
| Gross Profit | - - | 
         
    -
 
        
       | 
      |
| EBITDA | - - | 
         
    -
 
        
       | 
      |
| EBIT (Operating Income) EBIT | 1,841 1,841 | 
         
      
        
        92%
      
      
        
        92%
      
 
        
       | 
      |
| Net Profit | 1,021 1,021 | 
         
      
        
        52%
      
      
        
        52%
      
 
        
       | 
      |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.
| Head office | United Kingdom | 
| CEO | Pablo Legorreta | 
| Founded | 1996 | 
| Website | www.royaltypharma.com | 
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


